title: Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial.
abstract: OBJECTIVE
  Numerous studies have demonstrated the efficacy of serotonergic antidepres-sants, particularly the selective serotonin reuptake inhibitors (SSRIs), in the treatment of social phobia. We evaluated the efficacy, safety, and tolerability of nefazodone, a 5-HT(2) antagonist, in patients with generalized social phobia (GSP).
  
  
  METHODS
  One hundred five patients with GSP (confirmed using the Structured Clinical Interview for DSM-IV) from 4 Canadian outpatient anxiety clinics were assigned randomly to nefazodone (300-600 mg/day, flexible dose) or placebo for 14 weeks of double-blind treatment. Data were collected from October 12, 1999, through December 8, 2001. Primary efficacy outcomes were the Clinical Global Impressions-Improvement scale (CGI-I) score and the Liebowitz Social Anxiety Scale score.
  
  
  RESULTS
  In the intent-to-treat sample, 16 (31.4%) of 51 subjects taking nefazodone and 12 (23.5%) of 51 subjects taking placebo were rated as much or very much improved on the CGI-I at endpoint (chi(2) = 0.79, p = .38). With the exception of the Social Phobia Scale, no significant differences were found in measures of social phobia when comparing the nefazodone and placebo groups.
  
  
  CONCLUSIONS
  These findings suggest that nefazodone is not an effective agent in the treatment of GSP. These data parallel some recent findings with the use of the SSRI fluoxetine in GSP. The lack of efficacy of 2 serotonergic antidepressants in GSP suggests that serotonin reuptake inhibition may not be the only mechanism of action required for efficacy to occur in the treatment of GSP.
authors.affiliation: Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada. vanamer@mcmaster.ca
authors.forename: Michael
authors.initials: M
authors.lastname: Van Ameringen
authors.forename: Catherine
authors.initials: C
authors.lastname: Mancini
authors.forename: Jonathan
authors.initials: J
authors.lastname: Oakman
authors.forename: John
authors.initials: J
authors.lastname: Walker
authors.forename: Kevin
authors.initials: K
authors.lastname: Kjernisted
authors.forename: Pratap
authors.initials: P
authors.lastname: Chokka
authors.forename: David
authors.initials: D
authors.lastname: Johnston
authors.forename: Mark
authors.initials: M
authors.lastname: Bennett
authors.forename: Beth
authors.initials: B
authors.lastname: Patterson
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010698:Phobic Disorders / Q000188:drug therapy*; D010879:Piperazines; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D014230:Triazoles; C051752:nefazodone